

Special Issue

Advances in Pediatric Neuromuscular Disorders: Second Edition

Message from the Guest Editor

In the past decade, there has been a quantum leap in therapies for pediatric neuromuscular disorders. Diseases which were once untreatable, such as spinal muscular atrophy and Pompe disease, now have multiple therapies available including enzyme replacement therapy, post-transcription RNA modulators and gene therapy. Life expectancy and quality of life have improved for patients with Duchenne muscular dystrophy and other muscular dystrophies. Newer and safer agents are now available for previously treatable disorders, such as myasthenia gravis. Ongoing multifaceted research is taking place regarding early diagnosis, treatment and remedies to improve the quality of life and outcomes for patients with various neuromuscular disorders. Additionally, like everything in medicine, COVID-19 has introduced a new paradigm of neuromuscular diseases. This Special Issue aims to explore the frontier of the evolving field of neuromuscular medicine.

Guest Editor

Dr. Aravindhan Veerapandiyan

Pediatric Neurology, Arkansas Children's Hospital, 1 Children's Way,
Little Rock, AR 72202, USA

Deadline for manuscript submissions

closed (25 March 2025)



Children

an Open Access Journal
by MDPI

Impact Factor 2.1
CiteScore 3.8
Indexed in PubMed



mdpi.com/si/215126

Children
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
children@mdpi.com

[mdpi.com/journal/
children](https://mdpi.com/journal/children)





Children

an Open Access Journal
by MDPI

Impact Factor 2.1
CiteScore 3.8
Indexed in PubMed



[mdpi.com/journal/
children](https://mdpi.com/journal/children)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or comprehensive review for consideration and publication in *Children* (ISSN 2227-9067). *Children* is an open access journal—research articles, reviews, and other content are published online immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. The journal focuses on sharing clinical, epidemiological, and translational science relevant to children's health. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Paul R. Carney

Departments of Child Health and Neurology, University of Missouri, 400 Keene Street, Columbia, MO 65211, USA

Author Benefits

Open Access

— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Pediatrics) / CiteScore - Q2 (Pediatrics, Perinatology and Child Health)